How One Large Pharma's Global Phase I Trial Slashed Biospecimen Queries by Up to 80% With Slope
A top-10 large pharma sponsor deployed Slope's biospecimen lifecycle management platform across a subset of sites in a global Phase I clinical trial, creating a controlled, apples-to-apples comparison between Slope-enabled and non-Slope sites. The results were striking: Slope sites experienced 78% fewer urgent queries and 80.5% fewer total biospecimen-related queries per subject, while also resolving queries 37% faster than non-Slope sites. Critically, zero missing sample events occurred at Slope-enabled sites, whereas all missing sample incidents were recorded at non-Slope sites. These outcomes were achieved despite significant constraints — including no EDC integration, no lab kit integrations, and paper requisitions remaining in all kits — underscoring the platform's ability to deliver measurable operational improvements even in a limited deployment scenario.
In this guide, you'll explore
- 78% reduction in urgent queries per subject at Slope-enabled sites (0.42 vs. 2.9 per subject at non-Slope sites)
- 80.5% reduction in total biospecimen-related queries per subject across the trial
- Queries resolved 37% faster at Slope sites — closed in an average of 5 days vs. 8 days at non-Slope sites
- Zero missing sample events at Slope-enabled sites; all missing sample incidents occurred at non-Slope sites
- 34% kit waste rate achieved at the trial's highest-enrolling site, which used Slope — even without kit or EDC integrations